» Articles » PMID: 37941657

Pan-cancer Landscape of Immunology PIWI-interacting RNAs

Overview
Specialty Biotechnology
Date 2023 Nov 9
PMID 37941657
Authors
Affiliations
Soon will be listed here.
Abstract

PIWI-interacting RNAs (piRNAs), an emergent type of non-coding RNAs during oncogenesis, play critical roles in regulating tumor microenvironment. Systematic analysis of piRNAs' roles in modulating immune pathways is important for tumor immunotherapy. In this study, in-depth analysis of piRNAs was performed to develop an integrated computational algorithm, the immunology piRNA (ImmPI) pipeline, for uncovering the global expression landscape of piRNAs and identifying their regulatory roles in immune pathways. The immunology piRNAs show a tendency towards overexpression patterns in immune cells, causing perturbations in tumors, being significantly associated with infiltration of immune cells, and having prognostic value. The ImmPI score can contribute to prioritizing tumor-related piRNAs and distinguish two subtypes of SKCM (immune-cold and hot phenotypes), as characterized by different prognoses, immunogenicity and antitumor immunity. Finally, we developed an interactive web resource (ImmPI portal: http://www.hbpding.com/ImmPi) for the biomedical research community, with several useful modules to browse, visualize, and download the results of immunology piRNAs analysis. Overall, our work provides a comprehensive landscape of piRNAs across multiple cancer types and sheds light on their regulatory and functional roles in tumor immunity. These findings pave the way for future research and development of piRNA-based immunotherapies for cancer treatment.

Citing Articles

Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.

Cai J, Yan Z, Zhong Y, Li Y, Huang J, Hu H BMC Cancer. 2025; 25(1):319.

PMID: 39984879 PMC: 11846270. DOI: 10.1186/s12885-025-13672-5.


piRNA associates with immune diseases.

Jiang M, Hong X, Gao Y, Kho A, Tantisira K, Li J Cell Commun Signal. 2024; 22(1):347.

PMID: 38943141 PMC: 11214247. DOI: 10.1186/s12964-024-01724-5.


Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy.

Han R, Rao X, Zhou H, Lu L Int J Nanomedicine. 2024; 19:4803-4834.

PMID: 38828205 PMC: 11144010. DOI: 10.2147/IJN.S461289.

References
1.
Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

2.
Juzenas S, Venkatesh G, Hubenthal M, Hoeppner M, Du Z, Paulsen M . A comprehensive, cell specific microRNA catalogue of human peripheral blood. Nucleic Acids Res. 2017; 45(16):9290-9301. PMC: 5766192. DOI: 10.1093/nar/gkx706. View

3.
Osmani L, Askin F, Gabrielson E, Li Q . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017; 52(Pt 1):103-109. PMC: 5970946. DOI: 10.1016/j.semcancer.2017.11.019. View

4.
Delgado M, Leon J . Gene expression regulation and cancer. Clin Transl Oncol. 2006; 8(11):780-7. DOI: 10.1007/s12094-006-0132-7. View

5.
Zhou X, Liu J, Meng A, Zhang L, Wang M, Fan H . Gastric juice piR-1245: A promising prognostic biomarker for gastric cancer. J Clin Lab Anal. 2019; 34(4):e23131. PMC: 7171314. DOI: 10.1002/jcla.23131. View